Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection

Drugs

Volumn 55, Issue 3, 1998, Pages 461-486

  Perry, Caroline M ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

[7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE; ALPHA INTERFERON A; ASTEMIZOLE; BMS 186318; CISAPRIDE; CLARITHROMYCIN; DIDANOSINE; EMIVIRINE; ERGOT DERIVATIVE; ERYTHROMYCIN; GLUCOSE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; PROTEINASE; RANITIDINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TERFENADINE; TRIAZOLAM; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIVIRAL ACTIVITY; ATAXIA; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFUSION; DISEASE MARKER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; REVIEW; SEIZURE; SKIN MANIFESTATION; THROMBOCYTOPENIA; VIRUS LOAD; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; GELS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; SAQUINAVIR;

ATAXIA; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0031914446     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855030-00014     Document Type: Review

References (99)

1. Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996 Jul; 52: 93-112
2. Moyle G. Saquinavir: a review of its development, pharmacological properties and clinical use. Expert Opin Invest Drug 1996 Feb; 5: 155-67
3. Hoetelmans RMW, Meenhorst PL, Mulder JW, et al. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997 Aug; 19: 159-75
4. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996 Jun 15; 124: 1086-8
5. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997 Jan 8; 277: 145-53
6. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334: 1011-7
7. Vella S, Lazzarin A, Carosi G, et al. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antiviral Ther 1996 Aug; 1: 129-40
8. Clumek N et al. Clinical benefits of saquinavir (SQV) + zalcitabine (ddC) + zidovudine (ZDV) in untreated/minimally treated HIV-infected patients [abstract no. LB4]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto
9. F. Hoffmann-La Roche. Fortìvase™ (saquinavir) soft gelatin capsules. Prescribing information, 1997. (Data on file)
10. Gieschke R, Fotteler B, Buss N, et al. Relationship between exposure to saquinavir and surrogate markers of efficacy/toxicity in therapeutic study NV 15107. F. Hoffmann-La Roche, Research Report B-162305, 1997 Mar 12. (Data on file)
11. Beattie D, Bieska G, Buss N, et al. A randomized, parallel, open-label study comparing saquinavir hard gelatin formulation (600mg t.i.d.) to saquinavir soft gelatin formulation [(400 mg, 800 mg, 1200 mg) t.i.d.] × 8 weeks in HIV infected patients. F. Hoffmann-La Roche, Research Report W-144981/30, 1996 Sep 30. (Data on file)
12. Fischer L. Saquinavir SGC dose-ranging study. F. Hoffmann-La Roche, 1998. (Data on file)
13. F. Hoffmann-La Roche (Welwyn), 1998. (Data on file)
14. Hill G. 'Fortovase': optimising the benefits of saquinavir. Inpharma 1997; 1112 (13)
15. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51: 701-12
16. American Hospital Formulary Service Drug Information. Saquinavir Mesylate, 1997
17. Perry CM, Benfield P. Nelfinavir. Drugs 1997 Jul; 54: 81-7
18. Lea AP, Faulds D. Ritonavir. Drugs 1996 Oct: 52: 541-6
19. Moyle G. Saquinavir in the management of HIV infection. Br J Hosp Med 1997 Jun 4; 57: 560-4
20. Perno C-F, Aquaro S, Rosenwirth B, et al. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol 1994; 56: 381-6
21. 1 acid glycoprotein. J Infect Dis 1995; 171: 546-51
22. x. St Louis: Mosby, 1997
23. Demine CA, Bechtold CM, Stock D, et al. Evaluation of reverse transeriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996 Jun; 40: 1346-51
24. Bloom LA, Boritzki TJ, Patick AK. Evaluation of the antiviral activity and cytotoxicity of nelfinavir in combination with reverse transcriptase and protease inhibitors in an in vitro acute HIV-1 infection model [abstract]. Antiviral Res 1997 Apr; 34: 58
25. Oh M-d, Merrill DP, Sutton L, et al. Sequential versus simultaneous combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 infection in vitro. J Infect Dis 1997 Aug; 176: 510-4
26. Bold G, Capraro HG, Cozens R, et al. Profile of CGP61755 a novel and potent HIV-1 protease inhibitor that acts synergistically with saquinavir and AZT in vitro: consequences of clinical use [abstract]. Schweiz Med Wochenschr 1996; 126 Suppl. 74/II: 54
27. Merrill DP, Manion DJ, Chou T-C, et al. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. J Infect Dis 1997 Jul; 176: 265-8
28. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996 Aug; 52; 168-85
29. Boucher C. Rational approaches to resistance: using saquinavir. AIDS 1996 Nov; 10 Suppl. 1: S15-19
30. Roberts NA. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995 Dec; 9 Suppl. 2: 27-32
31. Maschera B, Darby G, Palu G, et al. Human immunodeficiency virus: mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem 1996 Dec 27; 271: 33231-5
32. F. Hoffmann-La Roche. Study of proteinase genotypes after 16 weeks therapy with two formulations of saquinavir in combination with NRTI of choice. F. Hoffmann-La Roche, 1997. (Data on file)
33. F. Hoffmann-La Roche. SQV-SGC and HIV proteinase genotype in clinical trials. F. Hoffmann-La Roche, 1997. (Data on file)
34. Race F, Gilbert SM, Sheldon JG, et al. Low occurrence of reduced sensitivity to saquinavir in antiviral combination: results from a phase III clinical trial (NV14256) [abstract]. AIDS 1996 Nov; 10 Suppl. 2: 22
35. Race E, Gilbert SM, Tomlinson PW, et al. Long term treatment with saquinavir (invirase), does not lead to a significant reduction in sensitivity to MK-639 [abstract]. 11th International Conference on AIDS; 1996 Jul 7-12; Vancouver, 285-6
36. Tomlinson PW, Craig JC, Moffatt AR, et al. HIV-1 from patients in a phase II clinical trial with the proteinase inhibitor (PI) saquinavir (SQV) taken in combination with RT inhibitors (RTIs) exhibits very little reduced sensitivity to other PI's [abstract]. AIDS 1996 Nov; 10 Suppl. 2: S21
37. Race E, Gilbert SM, Sheldon JG, et al. An overview of drug resistance during saquinavir treatment. AIDS 1996 Nov: 10 Suppl. 2: 11
38. Kaye S, Pym AS, Galpin S, et al. Changes in virological markers during prolonged saquinavir monotherapy [abstract]. AIDS 1996 Nov; 10 Suppl. 2: S22
39. Craig C, Race E, Sheldon J, et al. Key amino acid substitutions in HIV proteinase remain unaltered during increased exposure to saquinavir (SQV-SGC): results from preliminary clinical trials [abstract]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15; Hamburg, 30
40. Duncan IB, Patick AK, Gilbert S, et al. Genotypic analysis of HIV protease in patients undergoing combination therapy with saquinavir and nelfinavir [abstract]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28; St Petersburg (FL)
41. Decks S, Eastman S, Horton C, et al. Addition of saquinavir-soft gel capsule to existing ARV therapy: virologic predictors of response [abstract]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28; St Petersburg (FL)
42. Craig C, Race E, O'Sullivan E, et al. Increased exposure to the HIV protease inhibitor saquinavir (SGV) does not alter the nature of key resistance mutations [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
43. Kravcik S, Sahai J, Kerr B, et al. Protease gene mutations and long term follow-up of HIV-infected patients treated with nelfinavir mesylate (NfV) plus saquinavir-soft gel capsule (SQV-SGC). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, 278
44. Kravcik S, Farnsworth A, Patrick A, et al. Long term follow-up of combination protease inhibitor therapy with nelfinavir and saquinavir (soft gel) in HIV infection [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
45. Schmit JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996 Aug; 10: 995-9
46. Shapiro J. HAART: planning for the future [oral presentation at Roche satellite symposium]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15: Hamburg
47. Schapiro JM, Winters M, Lawrence J, et al. Clinical and genotypic cross resistance between the protease inhibitors saquinavir and indinavir [abstract]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25-28; St Petersburg (FL)
48. Eastman PS, Duncan IB, Gee C, et al. Acquisition of genotypic mutations associated with reduced susceptibility to protease inhibitors during saquinavir monotherapy [abstract]. International Workshop on HIV Drug Resistance, Treatment Strategics and Eradication; 1997 Jun 25-28; St Petersburg (FL)
49. Lawrence J, Schapiro J, Pesano R, et al. Clinical response and genotypic resistance patterns of sequential therapy with nelfinavir followed by indinavir plus nevirapine in saquinavir/reverse transcriptase inhibitor-experienced patients [abstract]. International Workshop in HIV Drug Resistance. Treatment Strategies and Eradication: 1997 Jun 25-28; St Petersburg (FL)
50. Para MF, Collier A, Coombs R, et al. ACTG 333: antiviral effects of switching from saquinavir hard capsule (SQVhc) to saquinavir soft gelatin capsule (SQVsgc) vs. switching to indinavir (IDV) after prior saquinavir [abstract]. Infectious Diseases Society of America Annual Meeting; 1997 Sep 13-16; San Francisco
51. Bodsworth N, Slade M, Ewan J, et al. RTV and IND therapy at 28 weeks after 32 weeks' SQV therapy - influence of HIV-1 protease mutations [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
52. F. Hoffmann La-Roche (Basel), 1998. (Data on file)
53. Concha JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistannt to multiple protease inhibitors. Nature 1995; 374: 569-79
54. Craig JC, Duncan IB, Hockley D, et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991; 16: 295-305
55. Craig JC, Whittaker LN, Duncan IB, et al. In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959). Antiviral Chem Chemother 1994; 5: 380-6
56. Galpin S, Roberts NA, O'Connor T. Antiviral properties of the HIV-1 proteinase inhibitor RO-31-8959. Antiviral Chem Chemother 1994; 5: 43-5
57. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248: 358-61
58. Buss N, Gieschke R, Massarella J, et al. Summary of the human bioavailability, pharmacokinetics and pharmacodynamics of saquinavir. F. Hoffmann-La Roche. Research Report W-144010, 1997 Feb 14. (Data on file)
59. Buss N on behalf of the FSG. Saquinavir soft gel capsule (Fortovase): pharmacokineties and drug interactions [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, S16
60. Conway B. The activity and safety of two formulations of saquinavir combined with two nucleosides in treatment-naive patients [abstract]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15; Hamburg, 923
61. Merry C, Barry M, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in patients with HIV disease. AIDS 1996 Nov; 10 Suppl. 2: 13
62. Merry C, Barry MG, Mulcahy F, et al. Saquimivir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997; 11 (15): F117-20
63. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinect 1997 Mar; 32: 194-209
64. Moyle GJ, Sadler M, Hawkins D, et al. Correlation between plasma and CSF viral load in patients on saquinavir containing regimens. Pharmacokinetics (PK) of saquinavir at steady state in CSF and plasma. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15; Hamburg
65. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997 May; 175: 1063-70
66. Washington CB, Duran GE, Sikic BI, et al. Saquinavir is a high affinity substrate for the multidrug transporter p-glycoprotein [abstract]. 98th Annual Meeting of the American Society for Clinical Pharmacology and Experimental Therapeutics; 1997 Mar 5-8: San Diego, 193
67. Hoof T, Brandt T, Demmer A, et al. Interaction of HIV proteases inhibitors with MDR1 - competetive binding and resistance modulation. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28-Oct 1; Toronto, 1-111
68. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997 Feb; 25: 256-66
69. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients [abstract]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18: New Orleans, 6
70. Heylen R, Miller R. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2. Genitourin Med 1997 Feb; 73: 5-11
71. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997 Aug; 44: 190-4
72. Inaba T, Fischer N, Riddick DS, et al. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and KRM-1648 in human liver microsomes [abstract]. Pharmacologist 1997; 39 (1): 21
73. Kempt DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997 Mar; 41: 654-60
74. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997 Mar 15; 11: F29-33
75. McCrea J, Buss N, Stone J, et al. Indinavir-saquinavir single dose pharmacokinetic study [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
76. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate increases saquinavir-soft gel capsule exposure in HIV+ patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
77. Conway B, Kwiatkowski MB, Shillington A, et al. Pilot study of saquinavir enhanced oral formulation as adjunctive antiretroviral therapy in advanced HIV [abstract]. Can J Infect Dis 1997 Mar-Apr; 8 Suppl. A: 45A
78. Fletcher CV, Kline MW, Brundage RC, et al. Saquinavir soft gel capules combined with nucleoside antiretroviral agents in HIV-infected children. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15; Hamburg, 919
79. Kline MW, Fleteher CV, Brundage RC, et al. Combination therapy including saquinavir soft gelatin capsules (SQV-SGC) in HIV-infected children [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
80. F. Hoffmann-La Roche (Nutley), 1998. (Data on file)
81. Gill MJ, Beall G, Beallic D, et al. Safety of saquinavir soft gelatin capsule (SQV-SGC) in combination with other antiretroviral agents: multicenter study NV 15182: 24 week analysis. 37th Interscicnce Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto
82. Kravcik S, Seguin I, Sahai J, et al. Long term follow-up of a cohort of HIV infected persons treated with nelfinavir and saquinavir SGC in combination [abstract]. Can J Infect Dis 1997 Mar-Apr; 8 Suppl. A: 45A
83. Stellbrink HJ, van Lunzen J, Albrecht H, et al. Antiviral effect of triple drug combination therapy using saquinavir soft gelatin capsules [abstract]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15; Hamburg, 427
84. Sension M, Farthing C, Siemon-Hryczyk P, et al. Saquinavir soft gel capsule (SGC) in combination wtih AZT and 3TC in treatment naive patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, 1-190
85. Sension M, Farthing C, Palmer Pattison T, et al. FortivaseTM (saquinavir soft gel capsule; SQV-SGC) in combination with AZT and 3TC in antiretroviral-naïve HIV-1 infected patients [abstract]. 5th International Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, S19
86. Fischer L, Siemon-Hryczyk P, Pilson R, et al. Saquinavir soft gel capsule (SGC) in combination with AZT and 3TC in treatment naive patients [abstract]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection: 1997 Oct 11-15; Hamburg, 393
87. Borleffs JC, Boucher CA, Bravenboer B, et al. Saquinavir-soft gelatine capsules versus indinavir as part of AZT and 3TC containing triple therapy. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28-Oct 1; Toronto, 1-92
88. Borleffs JC et al. First comparative study of saquinavir soft gel capsules vs indinavir as part of triple therapy regimen in CHEESE [abstract]. 5th Conference of Retroviruses and Opportunistic Infections; 1998 Feb 1-5: Chicago, S15
89. Pozniak A et al. Study of protease inhibitors in combination in Europe (SPICE) [abstract]. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection; 1997 Oct 11-15: Hamburg
90. Opravil M et al. Study of protease inhibitor combination in Europe (SPICE); saquinavir soft gelatin capsule (SQV-SGC) and nelfinavir in HIV infected individuals [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
91. Beattie D, Bieska G, Leung P, et al. A randomized, parallel, open-label study comparing saquinavir hard gelatin formulation (600 mg t.i.d.) to saquinavir soft gelatin formulation [(400 mg, 800 mg. 1200 mg) tid] × 8 weeks in HIV infected patients: (24 week extension data). F. Hoffmann-La Roche, Research Report W-145012/6, 1996 Dec. (Data on file)
92. Ault A. FDA warns of potential protease-inhibitor link to hyperglycaemia. Lancet 1997 Jun 21; 349: 1819
93. Protease inhibitors and hyperglycaemia. Curr Probl Pharmacovig 1997 Sep; 23: 10
94. Winter AJ, Pywell JM, Ilchyshyn A, et al. Photosensitivity due to saquinavir. Genitourin Med 1997 Aug; 73: 323
95. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society USA Panel. JAMA 1997 Jun 25; 277: 1962-9
96. Gazzard BG, Moyle GJ, Weber J, et al. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1497 Apr 12; 349: 1086-92
97. HIV treatment: agressive therapy may use up options and divide opinion. Pharm J 1997 Aug 23; 259: 279
98. Department of Health and Human Services and the Henry J. Kaiser Family Foundation Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Department of Health and Human Services and the Henry J. Kaiser Familty Foundation; 1997 Nov 5 [Accessed 1998 Jan 16]. Available as Adobe Acrobat (PDF) file from: URL: http://www.hivatis.org/guide6.pdf
99. Double protease inhibitors - new gold standard in HIV. Scrip 1997 Oct 10 (2274): 18